# Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)

> **NCT04965636** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** Mepolizumab

## Key facts

- **NCT ID:** NCT04965636
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-14
- **Primary completion:** 2025-10-28
- **Final completion:** 2025-10-28
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965636, "Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04965636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*